Serum nesfatin-1 levels in overt and subclinical hyperthyroidism.
Journal: 2015/January - Minerva Endocrinologica
ISSN: 0391-1977
PUBMED: 25068306
Abstract:
OBJECTIVE
Nesfatin-1 was recently discovered anorexigenic peptide in the brain which is derived from nucleobindin-2. Central and peripheral administration of nesfatin-1, inhibits food intake, dose-dependently. Hyperthyroid patients have increased appetite and food intake with a craving for carbohydrate-rich food, at the beginning of disease, but the physiological mechanisms underlying this behavior is not known exactly. In this study, we investigated whether nesfatin-1 is involved in the regulation of appetite and body weight in hyperthyroidism, or not.
METHODS
A total of 70 patients with subclinical (35) and overt hyperthyroidism (35) compared with 35 control patients. Serum nesfatin-1 level was measured from all samples by commercial ELISA kit.
RESULTS
Serum nesfatin-1 levels were similar between three groups (P=0.293). After adjusting for age and body mass index, nesfatin-1 levels in control group was not different from subclinical and overt hyperthyroid group, respectively (P=0.567 and P=0.519).
CONCLUSIONS
These data showed that serum nesfatin-1 levels do not significant change in overt and subclinical hyperthyroidism.
Relations:
Diseases
(1)
Conditions
(2)
Chemicals
(7)
Genes
(1)
Organisms
(1)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.